Your browser doesn't support javascript.
loading
Residue histidine 50 plays a key role in protecting α-synuclein from aggregation at physiological pH.
Chi, Ying-Chih; Armstrong, Geoffrey S; Jones, David N M; Eisenmesser, Elan Z; Liu, Chang-Wei.
Afiliação
  • Chi YC; From the Department of Biochemistry and Molecular Genetics and.
  • Armstrong GS; Department of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado 80309.
  • Jones DN; Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado 80045 and david.jones@ucdenver.edu.
  • Eisenmesser EZ; From the Department of Biochemistry and Molecular Genetics and elan.eisenmesser@ucdenver.edu.
  • Liu CW; From the Department of Biochemistry and Molecular Genetics and changwei.liu@ucdenver.edu.
J Biol Chem ; 289(22): 15474-81, 2014 May 30.
Article em En | MEDLINE | ID: mdl-24742669
ABSTRACT
α-Synuclein (αSyn) aggregation is involved in the pathogenesis of Parkinson disease (PD). Recently, substitution of histidine 50 in αSyn with a glutamine, H50Q, was identified as a new familial PD mutant. Here, nuclear magnetic resonance (NMR) studies revealed that the H50Q substitution causes an increase of the flexibility of the C-terminal region. This finding provides direct evidence that this PD-causing mutant can mediate long range effects on the sampling of αSyn conformations. In vitro aggregation assays showed that substitution of His-50 with Gln, Asp, or Ala promotes αSyn aggregation, whereas substitution with the positively charged Arg suppresses αSyn aggregation. Histidine carries a partial positive charge at neutral pH, and so our result suggests that positively charged His-50 plays a role in protecting αSyn from aggregation under physiological conditions.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Alfa-Sinucleína / Histidina Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Alfa-Sinucleína / Histidina Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article